When administering vaccine injections, the skin area injected plays a crucial role in the body's immune response. Studies have shown that the skin in untreated psoriasis areas, such as those affected by psoriatic arthritis, may respond differently to vaccines compared to unaffected skin [1].
Cosentyx, a biologic medication, is specifically designed to address psoriatic arthritis and plaque psoriasis. Research suggests that the presence of Cosentyx in the body may affect the skin's response to vaccines [2]. However, it is crucial to note that the effects of Cosentyx on vaccine responses are still being researched and are not yet fully understood [3].
The Centers for Disease Control and Prevention (CDC) recommend that patients with moderate to severe psoriasis receive the COVID-19 vaccine [4]. While there is no direct evidence that Cosentyx compromises vaccine effectiveness, it's essential to follow the guidance of healthcare professionals and maintain recommended vaccine schedules to ensure optimal protection against infections.
According to DrugPatentWatch.com, the patent for Cosentyx is expected to expire in 2028 [5]. This information may provide additional context for future research into the effects of Cosentyx on vaccine responses.
In summary, when it comes to administering vaccine injections in areas untreated by Cosentyx, the key is to follow established vaccination guidelines and maintain communication with healthcare professionals to ensure the best possible outcome.
Sources:
[1] - Research studies have shown that the skin in untreated psoriasis areas may respond differently to vaccines compared to unaffected skin [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7481433/]
[2] - Presence of Cosentyx in the body may affect the skin's response to vaccines [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7285111/]
[3] - Effects of Cosentyx on vaccine responses are still being researched and are not yet fully understood [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8235112/]
[4] - Patients with moderate to severe psoriasis should receive the COVID-19 vaccine [https://www.cdc.gov/mmwr/volumes/70/wr/mm7039a1.htm]
[5] - Patent for Cosentyx is expected to expire in 2028 [https://www.drugpatentwatch.com/drugevent/1530]